Key Takeaways:
- Danaher Q2 EPS of $1.94 beat the $1.84 consensus estimate.
- Revenue rose 5.5% to $6.3 billion, topping forecasts of $6.11 billion.
- Full-year adjusted EPS guidance raised to a range of $8.45 to $8.60.
返回
Danaher beats Q2 estimates, raises full-year guidance on Life Sciences strength
Danaher reported Q2 earnings of $1.94 a share, beating the $1.84 consensus, as revenue rose 5.5% to $6.3 billion.
"Our Life Sciences businesses delivered their strongest quarter in several years," Chief Executive Rainer Blair said, adding that bioprocessing orders grew mid-teens in the quarter.
Net income climbed to $870 million, or $1.23 a share, from $555 million, or 77 cents a share, a year earlier. Revenue topped the $6.11 billion analysts had projected, according to FactSet.
For the third quarter, Danaher expects adjusted core revenue to increase 2% to 3%. The company raised its full-year adjusted EPS guidance to $8.45 to $8.60, up from $8.35 to $8.55, with adjusted core revenue growth of 3% to 4%.
Blair credited the quarter's performance partly to the Life Sciences segment, which delivered its strongest quarter in several years. While customer project timing affected bioprocessing revenue, underlying order trends remained strong, with bioprocessing orders growing at a mid-teens percentage rate during the quarter.
The company's diagnostics and biotechnology businesses also contributed to the top-line growth. Danaher, which operates across life sciences, biotechnology, and diagnostics, has benefited from continued end-market recovery and recent growth initiatives.
The guidance raise signals management expects the recovery in life sciences demand to continue. Investors will watch the Q3 earnings call for further detail on bioprocessing order momentum and segment margin trends.
This article is for informational purposes only and does not constitute investment advice.
